CATX Perspective Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$2.98

Period return

+0.31 (+11.61%)

Volume

777.9K

2026-07-21O $2.95 H $3.02 L $2.91 C $2.98MA5 $3.01MA20 $3.19MA60 $3.47MA120 $4.1

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 11.High2 months ago
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 05.LowBUY3 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 04. 20.LowBUY3 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 03. 23.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 19.LowBUY4 months ago
B. Riley Securities: Buy
US analyst rating / recommendation change.
2026. 03. 18.LowBUY4 months ago
UBS: Buy
US analyst rating / recommendation change.
2026. 03. 18.LowBUY4 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 03. 17.LowBUY4 months ago
RBC Capital: Outperform
US analyst rating / recommendation change.
2026. 03. 17.LowBUY4 months ago
BTIG: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $12.93 · 15 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Sector: Healthcare
Industry

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 05. 11.	After market close (AMC)	$-0.28	—	—	$84.18K	—	Scheduled
FY2023 Q3	2022. 09. 30.	Time TBD	—	—	—	—	$7.13M	Reported
FY2023 Q2	2022. 06. 30.	Time TBD	—	—	—	—	$5.42M	Reported
FY2023 Q1	2022. 03. 31.	Time TBD	—	—	—	—	$2.91M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,003,474	$4.18M	0.00%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,198,644	$3.3M	0.01%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	314,180	$864K	0.00%	—	New position

Perspective Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 05.	Wedbush	—	Maintain	Outperform → Outperform	—	Wedbush: Outperform
2026. 04. 20.	Wedbush	—	Maintain	Outperform → Outperform	—	Wedbush: Outperform
2026. 03. 23.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 19.	B. Riley Securities	—	Maintain	Buy → Buy	—	B. Riley Securities: Buy
2026. 03. 18.	UBS	—	Maintain	Buy → Buy	—	UBS: Buy
2026. 03. 18.	Wedbush	—	Maintain	Outperform → Outperform	—	Wedbush: Outperform